So the two key questions in protease-based drug discovery are: how specific should an inhibitor be to deliver a therapeutic outcome and what are the best ways to achieve the specificity needed?

Traws Pharma has completed the Phase I clinical trials of tivoxavir marboxil, a single-dose drug for treating or preventing H5N1 bird flu. The randomised, placebo-controlled, double-blind trial ...

Short chains of amino acids can form drug delivery nanoparticles and boost the properties of potential medicines ...

protease drug IdeXork (Xork) alongside Astellas' AT845, currently in the phase 1/2 FORTIS study in late-onset Pompe disease (LOPD) in adults. Xork is designed as a pre-treatment to overcome one of ...

Shionogi’s S-892216 is being developed as a pre-exposure prophylaxis (PrEP) drug for Covid-19. Credit: seksan Mongkhonkhamsao via Getty Images.

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Cocrystal Pharma (COCP – Research Report) today and set a price target of ...

In this video, Aruna Padmanabhan, MD, discusses the evaluation of PI3K inhibitor combinations as first-line treatment for patients with metastatic breast cancer.

Transmitted drug resistance (TDR ... of resistant viral strains from treated to untreated individuals. TDR to protease inhibitors, nucleoside reverse-transcriptase inhibitors and non-nucleoside ...

The proof-of-concept demonstrates the power of pairing AI with lab orchestration solutions to automate molecular screening for drug discovery.